Dr Reddy’s Laboratories (DRL) has launched Sildenafil tablets (20 mg), a bioequivalent generic version of Revatio (Sildenafil) Tablets in the US market, following the approval by the US FDA of DRL’s ANDA for Sildenafil tablets.
The Revatio brand had US sales of approximately $338.67 million for the most recent twelve months ending September 2012 according to IMS Health. DRL’s Sildenafil tablets in 20 mg are available in 90 count bottle sizes.
EP News Bureau